Research programme: small molecule antibacterial therapeutics - Ricerca Biosciences
Latest Information Update: 27 Mar 2009
At a glance
- Originator Eli Lilly
- Developer Ricerca Biosciences
- Class Small molecules
- Mechanism of Action FabH inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 20 Jan 2003 Preclinical trials in Bacterial infections in USA (unspecified route)